Redefining MRI:
From Image to Insight

ICMRI 2026
THE 14th INTERNATIONAL CONGRESS ON MRI
& 37th ANNUAL SCIENTIFIC MEETING OF KSMRM

AUGUST 27 - 28, 2026
Grand Walkerhill Seoul, Seoul, Korea
https://icmri.ksmrm.org/2026m

Neuro 1

SY01-1

Alzheimer's Disease in the Era of Anti-Amyloid Therapy: Standard Care, Imaging, and ARIA Management

Min Young Chun

Department of Neurology, Yongin Severance Hospital, Yonsei University College of Medicine, Korea

The therapeutic landscape of Alzheimer's disease (AD) has changed substantially with the introduction of anti-amyloid monoclonal antibodies. As these disease-modifying therapies (DMTs) enter routine clinical practice, neuroimaging has evolved from a diagnostic tool into an essential component of patient selection, treatment monitoring, and safety surveillance.

Current standards of care for anti-amyloid therapy require biomarker-based diagnosis, appropriate patient selection, and longitudinal imaging surveillance. The complementary roles of MRI, amyloid PET, cerebrospinal fluid, and plasma biomarkers throughout the treatment pathway are outlined, with particular emphasis on baseline MRI assessment and imaging findings that influence treatment eligibility.

Amyloid-related imaging abnormalities (ARIA), the most important adverse event associated with anti-amyloid therapy, are presented with respect to MRI surveillance protocols, characteristic imaging features, radiologic severity grading of ARIA-E and ARIA-H, major risk factors, and management based on MRI findings. The evolving role of MRI in supporting patient selection, treatment monitoring, and ARIA management is also highlighted.

Keywords: *Alzheimer's disease, Anti-amyloid therapy, Magnetic resonance imaging (MRI), Amyloid-related imaging abnormalities (ARIA), Biomarkers*